"Suffocating" tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy.

  • Tumor Immunotherapy and Microenvironment
September 07, 2021 By:
  • Janji B
  • Chouaib S.

We recently reported that inhibiting Hypoxia-inducible Factor-1alpha (Hif1a) transcriptional activity improves melanoma immunotherapy by driving immune cells into the tumor microenvironment (TME). This Author's View provides additional perspectives on how hypoxia inhibitors combined with immunotherapy can be used as innovative approaches to improve the therapeutic benefit of melanoma patients.

2021 Sep. Oncoimmunology.10(1):1968611.
Other information